Related Experiment Video
Updated: Sep 12, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
COVID-19-related posterior reversible encephalopathy syndrome: insights from a clinical case
1Department of Diagnostic and Interventional Radiology, Eberhard-Karls University, Tübingen, Germany.
Abstract:
In the present case report, a 50-year-old female presented with hemiparesis and blurred vision and was subsequently diagnosed with posterior reversible encephalopathy syndrome (PRES) associated with coronavirus disease 2019 (COVID-19). Magnetic resonance imaging revealed cortico-subcortical edema with hyperintensities bilaterally in the frontoparietal and bi-occipital regions. Although PRES is a neurotoxic disorder that typically affects white matter of the brain and often is associated with hypertension, renal failure, and autoimmune disorders, recent studies have suggested that COVID-19 increases the risk of PRES. This case report presents a unique instance of COVID-19-related PRES. Unlike most previously reported cases occurring during the acute phase of severe COVID-19, our patient experienced PRES during the recovery phase with mild initial symptoms, such as fatigue and mild fever. The article discusses the pathophysiology of PRES, the potential mechanisms by which COVID-19 leads to PRES, and the treatment and outcome of the patient.
Related Concept Videos
Viral Meningitis
Arboviral Encephalitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Brain Abscess l: Introduction
Hepatic Encephalopathy

